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Abstract
AIM: To establish if the juice of Moro , an anthocyanin-
rich orange, may improve liver damage in mice with 
diet-induced obesity. 
METHODS: Eight-week-old mice were fed a high-fat diet 
(HFD) and were administrated water or Moro juice for 12 
wk. Liver morphology, gene expression of lipid transcrip-
tion factors, and metabolic enzymes were assessed.
RESULTS: Mice fed HFD displayed increased body 
weight, insulin resistance and dyslipidemia. Moro  juice 
administration limited body weight gain, enhanced in-
sulin sensitivity, and decreased serum triglycerides and 
total cholesterol. Mice fed HFD showed liver steatosis 
associated with ballooning. Dietary Moro  juice mark-
edly improved liver steatosis by inducing the expres-
sion of peroxisome proliferator-activated receptor-α 
and its target gene acylCoA-oxidase , a key enzyme of 
lipid oxidation. Consistently, Moro  juice consumption 
suppressed the expression of liver X receptor-α and 
its target gene fatty acid synthase, and restored liver 
glycerol-3-phosphate acyltransferase 1 activity. 
CONCLUSION: Moro  juice counteracts liver steato-
genesis in mice with diet-induced obesity and thus may 
represent a promising dietary option for the prevention 
of fatty liver.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is a chronic 
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metabolic disorder with significant impact on cardiovas-
cular and liver-related mortality[1,2]. NAFLD is closely as-
sociated with obesity, dyslipidemia, diabetes and the full 
spectrum of  the metabolic syndrome[3,4], with insulin re-
sistance as a common pathophysiological determinant[5]. 
Lifestyle, that is, dietary habits and physical activity, 
plays a pivot role in the pathogenesis of  the metabolic 
syndrome[6]. Likewise, dietary factors have been shown 
to exert a major role in the development of  fatty liver[7]. 
Recently, the consumption of  foods and beverages con-
taining fructose has been identified as a risk factor for 
NAFLD[8]. Nonetheless, despite their fructose content, 
fruits are also rich in different polyphenolic compounds 
that exert several beneficial effects on health, mainly by 
modulating expression of  key enzymes involved in glu-
cose sensitivity and lipid homeostasis[9]. 
Anthocyanins (ACNs) are water-soluble plant poly-
phenolic pigments that confer a typical blue, red or pur-
ple color, and are contained especially in berries, blood 
oranges and pigmented corn and potato[10]. ACNs have 
been attributed several putative therapeutic roles, includ-
ing beneficial effects on obesity and related metabolic 
complications[11]. In this respect, Tsuda et al[12] firstly 
showed that ACN from purple corn prevented obesity, 
dyslipidemia and visceral fat inflammation in mice fed a 
high-fat diet (HFD). Recently, a further demonstration 
of  the putative hepatoprotective properties of  ACN has 
been provided by Liu et al[13], who observed that adminis-
tration of  protocatechuic acid, the major in vivo metabo-
lite of  the main ACN cyanidin-3-O-β-glucoside, reduced 
gene expression of  lipogenic enzymes in the liver, thus 
leading to a decreased hepatic lipid accumulation. In vitro 
and in vivo experiments suggest that ACNs can modulate 
gene expression of  several adipocytokines and regulate 
the pathways involved in lipogenesis and fat accumula-
tion[12,14]. ACNs are contained also in blood oranges, a 
variety of  sweet orange (Citrus sinensis) with an intense 
red pigmentation[15]. A recent study has demonstrated 
that blood orange consumption inhibits fat accumulation 
in mice[16] and may represent a promising dietary tool for 
the treatment of  obesity. 
In the current study, we aimed at clarifying whether 
consumption of  the juice of  Moro, a blood orange culti-
vated in Sicily, Italy, improved liver steatosis in mice fed 
HFD; a physiological model of  NAFLD and metabolic 
syndrome. 
MATERIALS AND METHODS
Animals and treatments 
All procedures fulfilled the Italian Guidelines for the 
Use and Care of  Laboratory Animals. Eight-week-old 
male C57BL6/J mice were purchased from Charles 
River Laboratories (Calco, Italy). Animals were main-
tained in a temperature- and light-controlled facility for 
12 wk. Diets were obtained by Harlan Teklad (Madison, 
WI, United States). The standard diet (SD) provided 3.3 
kcal/g with 60% carbohydrates, 23% proteins and 17% 
fat. The HFD provided 5.2 kcal/g with 60% fat, 20% 
proteins and 20% carbohydrates. Mice were distributed 
in three groups: group Ⅰ included six mice fed SD and 
permitted ad libitum consumption of  water (SD + water); 
group Ⅱ comprised six mice fed HFD and permitted 
ad libitum consumption of  water (HFD + water); group 
Ⅲ comprised six mice fed HFD and permitted ad libi-
tum consumption of  Moro orange juice instead of  water 
(HFD + Moro). Moro fruits were collected in the experi-
mental farm of  the Research Center for Citric Culture 
and Mediterranean Crops (Acireale, Italy). Fruits were 
immediately stored at 4 ℃ and squeezed a few days later; 
the juice obtained was pre-filtered and stored at -20 ℃ in 
aliquots of  0.5 L. Every 2 d, frozen juice aliquots were 
thawed, filtered and put in the bottle of  each cage. Fruit 
juice analysis was performed as previously described[16]. 
Food and beverage consumption was recorded twice 
weekly; body weight was recorded weekly. After sacrifice 
by CO2 asphyxiation, blood and liver samples were ob-
tained, processed and stored for further analysis. 
Histopathology
Formalin-fixed paraffin-embedded liver sections were 
stained with haematoxylin-eosin and Masson’s trichrome, 
using standard procedures. Liver injury was blindly eval-
uated according to the NAFLD activity score.
Biochemical analysis
Serum glucose, total cholesterol, triglycerides and alanine 
aminotransferase (ALT) were measured using Reflotron 
Plus system from Roche Diagnostic (Milan, Italy). Liver 
triglycerides content was measured using a serum/tis-
sue triglyceride colorimetric kit (Biovision, Mountain 
View, CA, United States). Insulin tolerance test (ITT) 
was performed on 5-h starved mice, and glycemia was 
measured immediately before and 15, 30 and 60 min 
after intraperitoneal injection of  0.4 U/kg recombinant 
human insulin. The total amount of  ACN in Moro juice 
was determined as previously described[16]. Glycerol-
3-phosphate acyltransferase 1 (GPAT1) activity was as-
sayed as previously described [17]. 
RNA extraction and real-time polymerase chain reaction 
Total RNA was extracted by homogenizing snap frozen 
liver samples in TRIzol reagent (Invitrogen, Milan, Italy). 
Quantitative real-time polymerase chain reaction (PCR) 
was performed in 7900HT Fast Real-Time PCR System 
Applied Biosystems (Applied Biosystems, Foster City, 
CA, United States), using the EXPRESS SYBR Green-
ER™ qPCR SuperMix with Premixed ROX (Invitrogen). 
Reactions were performed in a 20 µL mixture con-
taining cDNA, specific primers of  each gene, and the 
SYBRR GreenER™ qPCR SuperMix. The specific PCR 
products were detected by the fluorescence of  SYBR 
Green, the double-stranded DNA binding dye. The 
relative mRNA expression level was calculated by the 
threshold cycle (Ct) value of  each PCR product and 
normalized with that of  glyceraldehyde-3-phosphate de-
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hydrogenase by using comparative 2ΔΔCt method. Primer 
sequences are shown in Table 1. 
Statistical analysis
Statistical analysis was performed by GraphPad Prism 
software (San Diego, CA, United States). Data are the re-
sults of  three independent experiments. All results were 
expressed as mean ± SE. One-way analysis of  variance 
with Bonferroni post-hoc analysis was used for paramet-
ric data. Kruskal-Wallis test was used for non-parametric 
data. P values < 0.05 were considered significant.
RESULTS
Moro juice improves dyslipidemia and enhances insulin 
sensitivity 
Moro juice had an ACN content of  85 mg/L. Food intake 
was identical among the three experimental groups (SD 
+ water, 3.1 ± 0.5 g/d vs HFD + water, 3.0 ± 0.8 g/d vs 
HFD + Moro, 3.1 ± 0.7 g/d). The amount of  Moro juice 
intake (4.1 ± 0.75 mL/d) did not differ from the amount 
of  water intake in the control groups (4.0 ± 1.2 mL/d). 
All mice had similar body weight at the start of  the ex-
periment, and after 12 wk, mice fed HFD + water had 
higher body weight compared with SD mice (Figure 
1A). Strikingly, mice fed HFD + Moro had the same 
body weight gain as mice fed SD. This effect on body 
weight gain occurred despite the fact that mice fed HFD 
+ Moro received a 10% higher energy intake, due to the 
sugar content of  the juice, as compared to mice fed 
HFD + water (Figure 1A). Obese mice had increased se-
rum total cholesterol, triglycerides and ALT as compared 
to the SD group (Figure 1B-D). Moro juice decreased 
serum total cholesterol and triglycerides, and reduced 
serum ALT to the levels of  lean controls (Figure 1B-D). 
Furthermore, orange juice consumption significantly 
enhanced insulin sensitivity, as demonstrated by the area 
under curve derived from ITT, which was 8685 ± 516 in 
mice fed HFD + water and was reduced to 7225 ± 718 
in the HFD + Moro group (Figure 2).
Moro juice induces liver peroxisome proliferator-
activated receptor-α and inhibits liver lipogenesis 
Liver sections of  mice fed HFD + water showed moder-
ate steatosis with a panacinar pattern (Figure 3B), mild 
lobular inflammation, and diffuse hepatocyte ballooning. 
In the HFD + Moro group, steatosis was almost absent 
(Figure 3C). Consistently, lobular inflammation and bal-
looning degeneration was less pronounced throughout 
the hepatic parenchyma. Fibrosis, assessed by Masson’s 
trichrome, was not found in any mice after 12 wk HFD 
(data not shown). Biochemical analysis confirmed that 
Moro juice induced a marked decrease of  liver triglycer-
ide content in mice fed HFD (Figure 3D). 
HFD was associated with impaired expression of  key 
transcription factors and metabolic enzymes involved in 
lipid homeostasis. In particular, we found a decrease in 
the gene expression of  peroxisome proliferator-activated 
receptor (PPAR)-α (Figure 4A) and acyl-CoA oxidase 
(AOX) (Figure 4B) and a significant increase in the ex-
pression of  liver X receptor (LXR)-α (Figure 4C), fatty 
acid synthase (FAS) (Figure 4D) and hydroxy methyl-
glutaryl (HMG)-CoA reductase (Figure 4E). Moro juice 
markedly decreased the mRNA levels of  LXR-α, FAS 
and HMG-CoA reductase but augmented the mRNA 
levels of  PPAR-α and AOX (Figure 4A-E). Consistent 
with gene expression findings, GPAT1 activity was re-
stored to the levels of  lean animals by Moro juice con-
sumption (Figure 4F).
DISCUSSION
In this study, we explored the effect of  the consumption 
of  the juice of  Moro, an ACN-rich orange cultivated in 
the Mediterranean region, on liver steatosis in mice with 
diet-induced obesity. In previous experiments in mice 
fed SD, we observed that C57BL6 mice and other strains 
tolerated the substitution of  drinking water with orange 
juice as the only drinking source, had similar food intake, 
and did not show any behavioral abnormality. Here, we 
demonstrated that Moro juice drinking reversed most of  
the metabolic abnormalities exhibited by obese mice, in-
cluding fatty liver. 
Our results are in agreement with previous experi-
mental data suggesting that ACNs from different fruits 
and vegetables are able to exert beneficial effects on 
several metabolic aspects related to obesity[11]. One com-
mon effect of  ACN administration both in diet-induced 
and genetic models of  obesity is the reduction of  body 
weight and of  visceral fat. In this respect, Kwon et al[18] 
showed that ACN extracted from black soybean led to 
improvement in dyslipidemia and a decrease in visceral 
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  Gene name                   Forward                      Reverse 
  PPAR-α 5’-AGTCAAGGTGTGGCCCAAGGT-3’ 5’- TGTCTATCGGACACTAGCGGAGGC-3’
  AOX 5’-CTTGTTCGCGCAAGTGAGG-3’ 5’-CAGGATCCGACTGTTTACC-3’
  LXR-α 5’-TGCCATCAGCATCTTCTCTG-3’ 5’-GGCTCACCAGCTTCATTAGC-3’
  FAS 5’-AGCCCACGTCGTAGCAAACCA-3’ 5’-GCAGGGGCTCTTGACGGCAG-3’
  HMG-CoA reductase 5’-CCTGACACTGAACTGAAGCG-3’ 5’-TCTTTCCAG AACACAGCACG-3’
  GAPDH 5'-ACCACCATGGAGAAGGCCGG-3' 5'-CTCAGTGTAGCCCAAGATGC-3'
Table 1  Primer sequences for real-time polymerase chain reaction
PPAR: Peroxisome proliferator-activated receptor; AOX: Acyl-CoA oxidase; LXR: Liver X receptor; FAS: Fatty acid synthase; HMG: Hydroxy methylgluta-
ryl; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase .
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adiposity in rats fed HFD. Similarly, extracts from tart 
cherries ameliorate dyslipidemia and decrease liver fat 
content in genetically insulin-resistant rats[19], as does cy-
anidin 3-glucoside in db/db mice[20]. 
As regards the molecular events underlying the 
effects of  Moro on liver lipid metabolism, we demon-
strated that a major mechanism is induction of  PPAR-α. 
PPAR-α is a key transcription factor promoting lipolysis 
and lipid oxidation in different tissues[21]. Mice lacking 
PPAR-α develop obesity and liver steatosis[22]; similarly, 
the hepatic levels of  PPAR-α are decreased in patients 
with NAFLD[23], and pharmacological agonists are able 
to improve liver steatosis[24]. Previous studies have sug-
gested that PPAR-α induction is involved in the antis-
teatotic effect of  extracts containing ACNs in different 
models of  obesity[19,20]. Along with the promotion of  lip-
id oxidation, Moro juice consumption induced the inhibi-
tion of  lipogenesis. In this respect, a major mechanism 
for the antisteatotic effect is the reversion of  LXR-α 
expression. LXR-α is a nuclear hormone receptor that 
promotes lipogenesis[25], which is increased in the liver of  
patients with NAFLD[26]. LXR-α stimulates lipogenesis 
through upregulation of  enzymes of  de novo lipogenesis 
such as FAS[25]. Suppression of  LXR-α expression and 
activity exerts potent antisteatotic effects in the liver[27]; 
some flavonoids have been shown to inhibit LXR-α[28]. 
Besides the effects on lipid homeostasis, the benefi-
cial impact of  Moro on insulin sensitivity is also note-
worthy. Insulin resistance is the metabolic hallmark of  
patients with NAFLD[29]. Studies using the hyperinsu-
linemic-euglycemic clamp coupled with infusion tracers 
have demonstrated that hepatic fat content is directly 
related to insulin resistance in the liver, skeletal muscle, 
and adipose tissue of  obese subjects[5]. In contrast, re-
cent findings have demonstrated that liver triglyceride 
content, not visceral adipose tissue volume, predicts the 
impairment of  insulin sensitivity and of  very low den-
sity lipoprotein secretion in patients with obesity[30,31]. 
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Figure 2  Effects of Moro juice on insulin sensitivity. Insulin tolerance test was 
performed with 0.4 U/kg recombinant human insulin in the two groups of mice fed 
high-fat diet (HFD); area under curve of blood glucose was 8685 ± 516 in mice 
fed HFD + water and was reduced to 7225 ± 718 in HFD + Moro (P < 0.05).
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Figure 1  Effects of Moro juice on body weight and serum parameters. A: Body weight was markedly increased in mice fed high-fat diet (HFD) and was de-
creased to the levels of lean mice by Moro juice; B: Serum total cholesterol was significantly reduced in mice drinking Moro; C and D: Serum triglycerides (C) and 
alanine aminotransferase (ALT) (D) were restored to the levels of lean mice. aP < 0.05 vs standard diet (SD) + water; cP < 0.05 vs HFD + water.
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Although mice drinking Moro juice remained hypergly-
cemic, probably because of  the sugar content, the ITT 
unequivocally revealed that Moro juice exerted insulin-
sensitizing activity. An insulin-sensitizing effect has been 
demonstrated for ACN-rich extracts from bilberry in ge-
netically obese mice[32], and for dietary blueberry in mice 
fed HFD[33].
In conclusion, in this study, we demonstrated that the 
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Figure 3  Effects of Moro juice on liver histology and liver triglycerides content. A: Hematoxylin-eosin-stained liver sections showing normal histology in lean 
mice; B: Moderate panacinar steatosis and hepatocyte ballooning in mice fed high-fat diet (HFD); C: Liver sections of mice fed HFD + Moro showing absence of ste-
atosis and ballooning; D: Liver triglycerides content was significantly decreased in mice drinking orange juice. aP < 0.05 vs standard diet (SD) + water, cP < 0.05 vs 
HFD + water. Magnification: 10 ×.
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Figure 4  Effects of Moro juice on liver lipid homeostasis. Gene expression of (A) peroxisome proliferator-activated receptor (PPAR)-α and (B) acyl-CoA oxidase 
(AOX) was significantly increased in mice fed high-fat diet (HFD) + Moro, whereas gene expression of (C) liver X receptor (LXR)-α, (D) fatty acid synthase (FAS) and 
(E) hydroxy methylglutaryl (HMG)-CoA reductase was markedly reduced by orange juice; Liver glycerol-3-phosphate acyltransferase 1 (GPAT1) was increased in mice 
fed HFD + water and was restored to control levels in mice drinking Moro juice (F). aP < 0.05 vs standard diet (SD) + water, cP < 0.05 vs HFD + water.
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juice of  Moro exerts metabolic hepatoprotective effects 
due to changes in the expression of  several enzymes 
involved in lipid homeostasis. Thus, the dietary adminis-
tration of  this food may be effective in preventing liver 
steatosis, and may be considered as a nutritional ap-
proach for the prevention of  NAFLD. Clinical trials are 
now warranted.
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